New approach to prostate cancer screening needed, expert says

March 7, 2014 by Alison Barbuti, University of Manchester

(Medical Xpress)—The UK needs to invest in testing for those men most at risk of prostate cancer rather than follow a cast-the-net-wide approach targeting the whole population, a leading scientist from The University of Manchester has argued at an international conference this week.

Men in the UK are currently entitled to PSA blood test for prostate cancer once they reach the age of 50 and will be recommended to have a prostate biopsy if their PSA level is greater than their age-specific threshold. This practice leaves around 50,000 men in the UK having an unnecessary prostate biopsy every year which is painful, can cause bleeding and infection and rarely even death.

Professor Ken Muir, from The University of Manchester, is proposing the UK moves to a risk-based approach in the community – a move backed by Tackle Prostate Cancer – formerly the Prostate Cancer Support Federation.

The new approach is a computer generated risk assessment, which will be based on an extension of the Canadian Sunnybrook Risk Calculator (SRC) which utilises a combination of indicators including PSA, PSA free to total (both simple blood based tests), urine symptoms, age, family history, ethnicity and physical examination (DRE: Digital Rectal Exam). Men will only be put forward for if their is calculated to be greater than that of the normal male population. The calculator will also find more high-grade cancers, the ones that kill 10,000 men per annum, earlier so that they are treatable.

Manchester researchers surveyed more than 1,000 men and over 100 GPs about whether they would be happy with a risk-based approach to screening. The findings show over 80% of men expressed strong support and 77% of GPs were supportive.

The researchers now aim to further identify and include more risk markers and personalise the approach by also using predisposing genetic markers.

Professor Muir said that these markers would potentially replace the digital rectal examination, which in a primary care environment has proved a weak point and a social obstacle in some communities. This would make the calculator more efficient.

Individual personalised risk-calculators have been used in routine practice in many other countries across Europe, Canada and the USA, for some time but their use in the NHS Primary Care has not been investigated.

Professor Muir said: "There is a growing acceptance of using a combination of markers of risk to reduce the over-referral of patients for invasive further assessment and that this assessment should be made in Primary Care."

The European Randomised Screening for Prostate Cancer (ERSPC) trial highlighted limitations of using a PSA threshold in a trial on over 182,000 men across Europe and organisers estimate a risk-based approach to screening would save between a quarter and a third of unnecessary biopsies to detect the same number of cancers.

The Manchester team now hopes to run a trial with General Practices allocated to assess men at risk aged 50-75 but also aged 40-75 who are Afro-Caribbean or who have first degree relatives with prostate or breast cancer using two different approaches. The trial would allocate some of the participants through the risk calculator and the others would just have a PSA test. The results would be compared to ascertain the effectiveness of the risk profiling.

David Smith, Secretary of Tackle and the Patient Expert on the trial said: "Tackle, whose members have invested significant sums in the trial, are confident that the trial team under Professor Muir will produce a that is non-inferior. The detection of cancers of definite clinical significance will be increased while significantly reducing the number of needing to undergo biopsy."

Explore further: New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer

Related Stories

New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer

September 26, 2013
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.

Alternative PSA screening strategies could reduce harm

February 5, 2013
(HealthDay)—Compared with standard screening, alternative prostate-specific antigen (PSA) screening strategies could maintain good prostate cancer detection rates while reducing overdiagnoses and unnecessary biopsies, according ...

Digital rectal exam remains important part of prostate screening

March 18, 2013
(Medical Xpress)—The digital rectal exam is an important screening test that can discover prostate cancer that a prostate-specific antigen or PSA test may not, despite the higher sensitivity of the PSA test, according to ...

Organized screening for prostate cancer does more harm than good

September 30, 2013
Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm ...

Personalised prostate cancer screening may save thousands from unnecessary treatment

November 5, 2012
Targeting prostate cancer screening based on a man's age and genes could potentially save thousands of men from unnecessary treatment and save the NHS millions of pounds. The research is presented at the NCRI Cancer Conference ...

Recommended for you

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

Researchers create novel combination as potential therapy for high-risk neuroblastoma

June 18, 2018
Researchers at VCU Massey Cancer Center in Richmond, Virginia, have identified a promising target to reverse the development of high-risk neuroblastoma and potentially inform the creation of novel combination therapies for ...

Standard myelofibrosis drug can awaken 'dormant' lymphoma

June 18, 2018
Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life ...

Breast cancer researcher warns against online genetic tests

June 18, 2018
We have never been so fascinated by the secrets inside our cells.

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.